160 related articles for article (PubMed ID: 34389892)
1. Outcomes from the Use of Targeted Interventions to Increase Meningococcal Vaccination Rates in a Pediatric Clinic.
Podraza L; Vasudevan J; Hudson C; Jayan A; Varman M
J Community Health; 2022 Feb; 47(1):87-93. PubMed ID: 34389892
[TBL] [Abstract][Full Text] [Related]
2. Potential public health impact of a
Huang L; Snedecor SJ; Balmer P; Srivastava A
Postgrad Med; 2022 May; 134(4):341-348. PubMed ID: 33615973
[TBL] [Abstract][Full Text] [Related]
3. United States Physicians' Knowledge, Attitudes, and Practices Regarding Meningococcal Vaccination for Healthy Adolescents and Young Adults.
Herrera-Restrepo O; Bunniran S; Mond T; Davenport E; Wang J; Sweeney C; Marshall GS
J Adolesc Health; 2024 Jun; 74(6):1131-1138. PubMed ID: 38363244
[TBL] [Abstract][Full Text] [Related]
4. Parental awareness of Meningococcal B vaccines and willingness to vaccinate their teens.
Basta NE; Becker AB; Li Q; Nederhoff D
Vaccine; 2019 Jan; 37(4):670-676. PubMed ID: 30587431
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal vaccination in patients with newly diagnosed asplenia in the United States.
Ghaswalla PK; Bengtson LGS; Marshall GS; Buikema AR; Bancroft T; Schladweiler KM; Koep E; Novy P; Hogea CS
Vaccine; 2021 Jan; 39(2):272-281. PubMed ID: 33309081
[TBL] [Abstract][Full Text] [Related]
6. Meningococcal Vaccination of Adolescents in the United States: Past Successes and Future Considerations.
Presa J; Findlow J; Zimet GD
J Adolesc Health; 2024 Jun; 74(6):1068-1077. PubMed ID: 38430074
[TBL] [Abstract][Full Text] [Related]
7. Serogroup B meningococcal vaccination practice patterns on college campuses.
Haimowitz R; Torres R; Caleb S; Thompson D; Smith A; Ciotoli C; Dannenbaum M; Fu LY
Vaccine; 2020 Oct; 38(46):7350-7356. PubMed ID: 33010977
[TBL] [Abstract][Full Text] [Related]
8. Awareness, attitudes, and practices on meningococcal serogroup B vaccination in the United States among parents of older adolescents and among young adults.
Herrera-Restrepo O; Zhou Z; Krishnan A; Conley WJ; Oladele E; Multani JK; Tuly R; Shi L; Chen CC; Preiss S; Clements DE
Curr Med Res Opin; 2024 Jan; 40(1):125-140. PubMed ID: 38032143
[TBL] [Abstract][Full Text] [Related]
9. Meningococcal serogroup B vaccination series initiation in the United States: A real-world claims data analysis.
Packnett ER; Zimmerman NM; Novy P; Morgan LC; Chime N; Ghaswalla P
Hum Vaccin Immunother; 2023 Dec; 19(1):2165382. PubMed ID: 36715008
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
[TBL] [Abstract][Full Text] [Related]
11. Disparities in healthcare providers' interpretations and implementations of ACIP's meningococcal vaccine recommendations.
Huang L; Goren A; Lee LK; Li VW; Dempsey A; Srivastava A
Hum Vaccin Immunother; 2020 Apr; 16(4):933-944. PubMed ID: 31634035
[TBL] [Abstract][Full Text] [Related]
12. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
Burman C; Alderfer J; Snow VT
J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.
Mbaeyi S; Pondo T; Blain A; Yankey D; Potts C; Cohn A; Hariri S; Shang N; MacNeil JR
JAMA Pediatr; 2020 Sep; 174(9):843-851. PubMed ID: 32687590
[TBL] [Abstract][Full Text] [Related]
14. Parental awareness and utilization of meningococcal serogroup B vaccines in the United States.
Srivastava A; Dempsey A; Galitsky A; Fahimi M; Huang L
BMC Public Health; 2020 Jul; 20(1):1109. PubMed ID: 32664872
[TBL] [Abstract][Full Text] [Related]
15. Meningococcal vaccination: a discussion with all adolescents, whether college-bound or not.
Alderfer JT; Moran MM; Srivastava A; Isturiz RE
Postgrad Med; 2019 Nov; 131(8):551-554. PubMed ID: 31575310
[No Abstract] [Full Text] [Related]
16. Meningococcal B vaccination coverage among older adolescents in the United States.
La EM; Garbinsky D; Hunter S; Poston S; Novy P; Ghaswalla P
Vaccine; 2021 May; 39(19):2660-2667. PubMed ID: 33849722
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
18. Low Meningococcal Vaccination Rates Among Patients With Newly Diagnosed Complement Component Deficiencies in the United States.
Marshall GS; Ghaswalla PK; Bengtson LGS; Buikema AR; Bancroft T; Koep E; Novy P; Hogea CS
Clin Infect Dis; 2022 Aug; 75(1):155-158. PubMed ID: 34718466
[TBL] [Abstract][Full Text] [Related]
19. Perceptions and Knowledge About the MenB Vaccine Among Parents of High School Students.
Richardson E; Ryan KA; Lawrence RM; Harle CA; Young A; Livingston MD; Rawal A; Staras SAS
J Community Health; 2021 Aug; 46(4):808-816. PubMed ID: 33389475
[TBL] [Abstract][Full Text] [Related]
20. Protecting UK adolescents and adults against meningococcal serogroup B disease.
Vyse A; Ellsbury G; Madhava H
Expert Rev Vaccines; 2018 Mar; 17(3):229-237. PubMed ID: 29374982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
